reports
Shenzhen Kingdom Sci-tech Co Ltd: 1 director
A director at Shenzhen Kingdom Sci-tech Co Ltd bought 830,000 shares at 11.390CNY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Shijiazhuang Kelin Electric Co Ltd: 2 directors
Two Directors at Shijiazhuang Kelin Electric Co Ltd bought 824,800 shares at between 27.880CNY and 28.105CNY. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...
Fairfax Announces Purchase of 275,000 Subordinate Voting Shares for Ca...
Fairfax Announces Purchase of 275,000 Subordinate Voting Shares for Cancellation From Chairman and CEO, Prem Watsa TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) (“Fairfax”) announces that it has repurchased 275,000 subordinate voting shares (the “Purchased Shares”) for cancellation from its Chairman and Chief Executive Officer, Prem Watsa. The Purchased Shares are being repurchased by Fairfax at price of C$1,512.89 (the “Purchase Price”), or US$1,106.48, per share at an aggregate cost of approximately US$304.3 million. The Purchased Shar...
CNMC Goldmine Holdings Limited: 1 director
A director at CNMC Goldmine Holdings Limited sold 4,600,000 shares at 0.210SGD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Soomit Datta
Liberty LA (Buy, TP: $13, +50%) Liberty LA - Confidence in FCF grows,...
Updating estimates for Q1 we feel much better about hitting expectations for the FCF turnaround. CEO Balan Nair was sounding upbeat on the earnings call about hitting the $45m of monthly EBITDA in Puerto Rico, in our view (crucial to group FCF improvement), and we look at how to bridge that outlook from the reported Q1 number. We push up 2025 Puerto Rico EBITDA.
Chocoladefabriken Lindt & Sprungli AG: 1 director
A director at Chocoladefabriken Lindt & Sprungli AG sold 526 shares at 10,685.551CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Aksa Akrilik Kimya Sanayii A S: 1 director
A director at Aksa Akrilik Kimya Sanayii A S bought 383,000 shares at 120.300TRY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure Announce Proposed Merger Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmac...
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks Alm. Brand A/S share buy-back program Transactions during 06 May 2024 – 08 May 2024On 5 December 2023, Alm. Brand A/S announced a share buy-back program of up to DKK 250 million, as described in company announcement no. 23/2023. On 8 February 2024, Alm. Brand A/S announced an increase of the existing share buy-back programme by DKK 100 million to DKK 350 million and extension of the period for the programme until and including 30 September 2024, as described in company announcement no. 09/2024. The program is carried out in accordance with ...
dLab erhåller en order om cirka 800 000 SEK av Gotlands Energi AB
dLab erhåller en order om cirka 800 000 SEK av Gotlands Energi AB Lund, 13 maj 2024 Dlaboratory Sweden AB (publ) meddelar idag att bolaget har erhållit en order om cirka 800 000 SEK från Gotlands Energi AB. Ordern avser dLabs intelligenta platform där Gotlands Energi väljer att påbörja övervakning av sitt elnät med hjälp av applikationerna dAnalyzer och dQuality för att förbättra leveranskvalitén i elnätet. Ordern kommer att levereras och installeras under augusti 2024 och medför en engångsintäkt om cirka 660 000 SEK, samt en årligt åtekommande avgiftsintäkt om ytterligare cirka 130 00...
Avalo Reports First Quarter 2024 Financial Results and Provides Busine...
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110 million as of March 31, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024. “Over the past month we have made considerable progress toward initiating our planned Phase 2 trial of AVTX-009 in hid...
Spectral Medical Announces First Quarter Results and Provides Corporat...
Spectral Medical Announces First Quarter Results and Provides Corporate Update Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throu...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results – Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company develop...
Titan Medical Reports Financial Results for the First Quarter 2024
Titan Medical Reports Financial Results for the First Quarter 2024 TORONTO, Ontario, May 13, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three months ended March 31, 2024. Recent Activities: On March 18, 2024, the Company announced it has entered into a definitive amalgamation agreement (the “Definitive Agreement”) with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction (the “Transaction”). Under the terms of the Definitive Agreement, a newly incorporated and whol...
Annovis Bio Provides Corporate Updates and Announces First Quarter 202...
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer’s disease (AD). Significantly higher rate of improvement...
Plus Therapeutics to Announce First Quarter Financial Results and Host...
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 15, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and pr...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase ...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population - In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM participants...
Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vo...
Leading Independent Proxy Advisory Firm ISS Recommends Shareholders Vote “FOR” All of Crown Castle’s Director Nominees Crown Castle Urges Shareholders to Vote “FOR” ONLY Crown Castle’s 12 Highly Qualified Nominees on the WHITE Proxy Card or Voting Instruction Form Today HOUSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today announced that Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that shareholders vote on the WHITE proxy card or voting instruction form “FOR” ONLY all 12 of...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appoint...
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other i...
Avicanna Announces Results of Study in Patients with Epidermolysis Bul...
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch.55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of the retrospective obser...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.